RxDoctor Payments DataLook up a doctor →

Daniel Gozzi, MD

Endocrinology, Diabetes & Metabolism · Suitland, MDNPI 1316931413

Payments from drug & device makers

$1,219,952in general payments, 2019–2025

Across 2,381 payments — averaging $512.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$533K
  • Novo Nordisk$358K
  • Sanofi-aventis U.S. LLC$217K
  • AbbVie$55K
  • AstraZeneca$30K
  • Boehringer Ingelheim$10K
  • plus $18K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC859$532,510
Novo Nordisk477$357,830
Sanofi-aventis U.S. LLC242$216,575
AbbVie(2 entities)89$54,714
AstraZeneca(2 entities)121$29,557
Boehringer Ingelheim63$10,337
Mannkind Corporation61$5,003
Amneal Pharmaceuticals LLC72$1,856
Sanofi1$1,607
Xeris Pharmaceuticals, Inc.37$1,220
Cequr Corporation4$1,096
Corcept Therapeutics47$1,079
Abbott49$836
Amgen(2 entities)30$558
Bayer20$439
Insulet Corporation12$289
Dexcom, Inc.9$276
Radius Health, Inc.14$275
Novartis12$271
BETA Bionics, Inc.7$228
Intuity Medical Inc7$228
Madrigal Pharmaceuticals5$219
Tandem Diabetes Care, Inc.7$214
Recordati_rare_diseases_inc.10$196
Astellas Pharma US Inc9$194
Merck11$166
Amarin Pharma, Inc.9$151
Medtronic(2 entities)7$144
Ascendis Pharma Endocrinology Inc6$143
Zealand Pharma US, Inc.5$131
Antares Pharma, Inc.6$131
Lifescan, Inc.4$101
Senseonics, Incorporated1$100
Acerus Pharmaceuticals Corporation5$95
Shire North American Group Inc5$92
Ascensia Diabetes Care US Inc.4$85
Johnson & Johnson4$78
BD3$77
Currax Pharmaceuticals LLC5$74
Clarus Therapeutics Inc.5$68
Esperion Therapeutics, Inc.3$62
IBSA Pharma Inc.3$60
Embecta Corp.2$52
EUSA Pharma (US) LLC3$52
Tolmar, Inc.3$49
Vivus LLC4$49
Pfizer2$41
Regeneron Healthcare Solutions, Inc.2$37
Averitas Pharma Inc.1$33
Nevro Corp.1$30
Coloplast1$28
Cumberland Pharmaceuticals, Inc.1$27
Ultragenyx Pharmaceutical Inc.1$26
Eisai Inc.2$26
Chiesi USA, Inc.1$24
Neurocrine Biosciences, Inc.1$22
Amphastar Pharmaceuticals, Inc.1$22
Sequel Med Tech, LLC1$19
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$18
Valeritas, Inc.1$14

How this compares

$1,219,952 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland →

Medicare billing

Part B allowed, 2024
$272,844
Medicare patients
569
Services billed
3,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Suitland

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →